Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
BIOMERICA INC (BMRA) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/26/2023 8-K Quarterly results
04/25/2023 8-K Quarterly results
03/07/2023 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "BIOMERICA, INC. UNDERWRITING AGREEMENT",
"Letter re: Shares of Common Stock of Biomerica, Inc.",
"Biomerica Announces Proposed Underwritten Public Offering of Common Stock",
"Biomerica Announces Pricing of $8 Million Underwritten Public Offering of Common Stock",
"Biomerica Announces Closing of $8 Million Underwritten Public Offering of Common Stock IRVINE, Calif., March 07, 2023-Biomerica, Inc. , a global provider of advanced medical products, announced today the closing of its previously announced underwritten public offering of an aggregate of 3,333,333 shares of its common stock, par value $0.08 per share, at a price to the public of $2.40 per sharefor total gross proceeds of $8 million, before deducting underwriting discounts and commissions and other offering-related expenses payable by Biomerica. All of the shares of common stock sold in the offering were offered by Biomerica. Craig-Hallum Capital Group LLC acted as sole managing underwriter in connection with the offering. Biomerica intends to use the net proceeds of the offering for general..."
03/02/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/07/2023 8-K Investor presentation
Docs: "FORM 8-K"
12/29/2022 8-K/A Quarterly results
12/16/2022 8-K Quarterly results
12/16/2022 8-K Quarterly results
12/09/2022 8-K Quarterly results
12/09/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
04/19/2022 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
Docs: "Letter from PKF San Diego, LLP"
02/10/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Biomerica Announces Positive Topline Results from the Endpoint Clinical Trial of its InFoods IBS Treatment for Patients with Irritable Bowel Syndrome InFoods® IBS Diagnostic-Guided Therapy is the first therapy of its kind using science, diet and technology to identify patient specific foods, which when eliminated, help reduce the symptoms of IBS without the use of drugs Multiple endpoints demonstrated statistically significant improvements, indicating that the elimination of specific foods may meaningfully reduce the symptoms of IBS in all subtypes Greatest clinical improvements, including but not limited to pain and bloating, were seen in patients diagnosed with IBS-Mixed and IBS-Constipation The InFoods® IBS trial was run at leading medical institutions including Mayo Clinic, Beth Israel..."
12/16/2021 8-K Quarterly results
12/10/2021 8-K Quarterly results
12/07/2021 8-K Quarterly results
09/30/2021 8-K Quarterly results
06/24/2021 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "Biomerica Signs Exclusive Distribution Agreement in Canada for its New and Proprietary Helicobacter Pylori Test, hp+detect"
01/22/2021 8-K Other Events, Financial Statements and Exhibits
Docs: "Opinion of Stradling Yocca Carlson & Rauth, P.C"
01/13/2021 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "EXHIBIT99_1"
12/11/2020 8-K Submission of Matters to a Vote of Security Holders
12/11/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/29/2020 8-K Quarterly results
05/08/2020 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "Biomerica Receives CE mark for New High-Volume Version of 10 Minute Test for COVID-19 Exposure and Expands International Distribution o New high-volume production test allows Biomerica to expand international distribution to better meet demand of its 10-minute test for coronavirus exposure. The test can be performed anywhere by trained professionals, e.g. airports, schools, work, doctor’s office utilizing blood from a finger prick. o Biomerica also announced it is now filling and has shipped commercial orders of its previously announced version of the product to Company distributors who are supplying customers that include NATO, and government agencies in Germany, Switzerland and the Netherlands. o The suggested price point of the new high-volume test maintains at $10 per patient price."
04/06/2020 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Biomerica Signs Two Definitive Agreements with Mount Sinai Medical School in New York to Scale-up a Laboratory Version Serological Test for COVID-19 That Enables High-Volume Screenings in Labs - Price point of this high-volume laboratory version test is expected be as low as $10 per patient - Once developed and scaled-up, Biomerica's existing production capacity could allow for over 1,000,000 tests per month at its manufacturing facilities in Irvine, California"
03/20/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Opinion of Stradling Yocca Carlson & Rauth, P.C"
03/17/2020 8-K Quarterly results
02/27/2020 8-K Quarterly results
01/09/2020 8-K Investor presentation
12/13/2019 8-K Submission of Matters to a Vote of Security Holders
09/04/2019 8-K Other Events
06/05/2019 8-K Other Events
04/09/2019 8-K Other Events
03/21/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy